| Mi Chang, MD | |
|
25825 Vermont Ave, Harbor City, CA 90710-3518 | |
| (424) 328-2580 | |
| Not Available |
| Full Name | Mi Chang |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 23 Years |
| Location | 25825 Vermont Ave, Harbor City, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174675557 | NPI | - | NPPES |
| 00A811610 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | A81161 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital - South Bay | Harbor city, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southern California Permanente Medical Group | 6002729175 | 7951 |
News Archive
Researchers at Sanford-Burnham Medical Research Institute have discovered a mechanism that explains why some breast cancer tumors respond to specific chemotherapies and others do not. The findings highlight the level of glutamine, an essential nutrient for cancer development, as a determinant of breast cancer response to select anticancer therapies, and identify a marker associated with glutamine uptake, for potential prognosis and stratification of breast cancer therapy.
BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared to placebo for the treatment of painful diabetic neuropathy did not meet statistical significance, although certain secondary endpoints showed statistically significant improvement over placebo. In addition, a strong safety profile for the product was observed.
Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that it has opened enrollment for a Phase Ib clinical trial with the National Cancer Institute's Adult Brain Tumor Consortium (ABTC) using the company's first product candidate mibefradil.
Research carried out at the Peninsula College of Medicine and Dentistry (PCMD), University of Exeter, has concluded that it would be a safe and cost-effective strategy to screen people with type 2 diabetes who have not yet developed diabetic retinopathy, for the disease once every two years instead of annually.
The microbial population in the air of the New York City subway system is nearly identical to that of ambient air on the city streets. This research, published ahead of print in the journal Applied and Environmental Microbiology, establishes an important baseline, should it become necessary to monitor the subway's air for dispersal of potentially dangerous microbes.
› Verified 1 days ago
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770515280 PECOS PAC ID: 6002729175 Enrollment ID: O20031110000678 |
News Archive
Researchers at Sanford-Burnham Medical Research Institute have discovered a mechanism that explains why some breast cancer tumors respond to specific chemotherapies and others do not. The findings highlight the level of glutamine, an essential nutrient for cancer development, as a determinant of breast cancer response to select anticancer therapies, and identify a marker associated with glutamine uptake, for potential prognosis and stratification of breast cancer therapy.
BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared to placebo for the treatment of painful diabetic neuropathy did not meet statistical significance, although certain secondary endpoints showed statistically significant improvement over placebo. In addition, a strong safety profile for the product was observed.
Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that it has opened enrollment for a Phase Ib clinical trial with the National Cancer Institute's Adult Brain Tumor Consortium (ABTC) using the company's first product candidate mibefradil.
Research carried out at the Peninsula College of Medicine and Dentistry (PCMD), University of Exeter, has concluded that it would be a safe and cost-effective strategy to screen people with type 2 diabetes who have not yet developed diabetic retinopathy, for the disease once every two years instead of annually.
The microbial population in the air of the New York City subway system is nearly identical to that of ambient air on the city streets. This research, published ahead of print in the journal Applied and Environmental Microbiology, establishes an important baseline, should it become necessary to monitor the subway's air for dispersal of potentially dangerous microbes.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mi Chang, MD 25825 Vermont Ave, Harbor City, CA 90710-3518 Ph: () - | Mi Chang, MD 25825 Vermont Ave, Harbor City, CA 90710-3518 Ph: (424) 328-2580 |
News Archive
Researchers at Sanford-Burnham Medical Research Institute have discovered a mechanism that explains why some breast cancer tumors respond to specific chemotherapies and others do not. The findings highlight the level of glutamine, an essential nutrient for cancer development, as a determinant of breast cancer response to select anticancer therapies, and identify a marker associated with glutamine uptake, for potential prognosis and stratification of breast cancer therapy.
BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint in the Phase 3 clinical study of Clonidine Topical Gel compared to placebo for the treatment of painful diabetic neuropathy did not meet statistical significance, although certain secondary endpoints showed statistically significant improvement over placebo. In addition, a strong safety profile for the product was observed.
Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that it has opened enrollment for a Phase Ib clinical trial with the National Cancer Institute's Adult Brain Tumor Consortium (ABTC) using the company's first product candidate mibefradil.
Research carried out at the Peninsula College of Medicine and Dentistry (PCMD), University of Exeter, has concluded that it would be a safe and cost-effective strategy to screen people with type 2 diabetes who have not yet developed diabetic retinopathy, for the disease once every two years instead of annually.
The microbial population in the air of the New York City subway system is nearly identical to that of ambient air on the city streets. This research, published ahead of print in the journal Applied and Environmental Microbiology, establishes an important baseline, should it become necessary to monitor the subway's air for dispersal of potentially dangerous microbes.
› Verified 1 days ago
Randel R. King, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 25825 Vermont Ave, Harbor City, CA 90710 Phone: 310-325-5111 | |
Ryokei K. Imai, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 25825 Vermont Ave, Harbor City, CA 90710 Phone: 310-325-5111 | |
Jennifer Wing-yun Lam, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 25825 Vermont Ave, Harbor City, CA 90710 Phone: 310-325-5111 | |
Jeffrey L. Wang, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 25825 Vermont Ave, Harbor City, CA 90710 Phone: 310-325-5111 | |
Dr. Lawrence R Tom, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 25825 Vermont Ave, Harbor City, CA 90710 Phone: 424-251-7140 | |
Howard K. Baik, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 25825 Vermont Ave, Harbor City, CA 90710 Phone: 310-325-5111 | |
Morgan Y. Chen, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 25825 Vermont Ave, Harbor City, CA 90710 Phone: 310-325-5111 |